Andrea Lobo,  —

Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.

Articles by Andrea Lobo

Trial of VQ-101 for patients with GBA gene mutations begins dosing

The first patient has been dosed in a first-in-human trial testing Vanqua Bio’s VQ-101 as an oral therapy for Parkinson’s disease linked to mutations in the GBA gene, the company has announced. The Phase 1 clinical trial is assessing the safety, tolerability, and pharmacological properties of VQ-101 in both…

NIH $1.9M research grant will fund detailed study of amyloid fibrils

A five-year project funded by a National Institutes of Health (NIH) research grant totaling nearly $1.9 million will study amyloid fibrils, protein clumps that are a hallmark of Parkinson’s disease and other neurodegenerative conditions. This work may shed new light on the disease-causing mechanisms related to these fibrils —…

AI platform will design precision Parkinson’s, neurological therapies

Manifest Technologies has completed initial funding and a partnership with Johnson & Johnson to apply its artificial intelligence (AI)-powered platform toward developing precision treatments for neurological diseases, including Parkinson’s disease, the company announced. The NAIO (Neuroscience and Artificial Intelligence Optimized) platform integrates neuroimaging data from humans and…

Produodopa available to treat advanced Parkinson’s in Scotland

Produodopa (foslevodopa/foscarbidopa; also known as ABBV-951), a continuous infusion formulation of levodopa/carbidopa, will be available to advanced Parkinson’s disease patients in Scotland whose severe motor fluctuations and involuntary movements are no longer controlled by those standard therapies. The Scottish Medicines Consortium (SMC) restricted use of AbbVie’s subcutaneous…

Investigational Parkinson’s therapy ALX-001 advances to Phase 2 trial

Allyx Therapeutics will advance into Phase 2 clinical development of ALX-001, its investigational therapy for neurodegenerative conditions, in people with Parkinson’s disease. The company announced the move alongside the presentation of positive data from a Phase 1b study (NCT05804383) at the International Conference on Alzheimer’s and…

Fosgonimeton shows potential as dementia treatment, Athira says

Athira Pharma’s fosgonimeton (ATH-1017) shows promise as a therapy for neurodegenerative conditions including Parkinson’s disease, according to data presented at the recent International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2024), in Portugal. The investigational small molecule demonstrated “encouraging pro-cognitive effects” in the exploratory…

Bemdaneprocel still shows benefits 1.5 years after treatment in trial

Use of bemdaneprocel (BRT-DA01), BlueRock Therapeutics’ investigational cell-based therapy, was found to be safe and well tolerated among people with Parkinson’s disease 1.5 years after treatment in a Phase 1 clinical trial. Moreover, the data also showed both that cells survived in the brain even after patients stopped…